Cargando…

Creation of nano eye-drops and effective drug delivery to the interior of the eye

Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-si...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikuta, Yoshikazu, Aoyagi, Shigenobu, Tanaka, Yuji, Sato, Kota, Inada, Satoshi, Koseki, Yoshitaka, Onodera, Tsunenobu, Oikawa, Hidetoshi, Kasai, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349510/
https://www.ncbi.nlm.nih.gov/pubmed/28290486
http://dx.doi.org/10.1038/srep44229
_version_ 1782514479432466432
author Ikuta, Yoshikazu
Aoyagi, Shigenobu
Tanaka, Yuji
Sato, Kota
Inada, Satoshi
Koseki, Yoshitaka
Onodera, Tsunenobu
Oikawa, Hidetoshi
Kasai, Hitoshi
author_facet Ikuta, Yoshikazu
Aoyagi, Shigenobu
Tanaka, Yuji
Sato, Kota
Inada, Satoshi
Koseki, Yoshitaka
Onodera, Tsunenobu
Oikawa, Hidetoshi
Kasai, Hitoshi
author_sort Ikuta, Yoshikazu
collection PubMed
description Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment.
format Online
Article
Text
id pubmed-5349510
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53495102017-03-17 Creation of nano eye-drops and effective drug delivery to the interior of the eye Ikuta, Yoshikazu Aoyagi, Shigenobu Tanaka, Yuji Sato, Kota Inada, Satoshi Koseki, Yoshitaka Onodera, Tsunenobu Oikawa, Hidetoshi Kasai, Hitoshi Sci Rep Article Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment. Nature Publishing Group 2017-03-14 /pmc/articles/PMC5349510/ /pubmed/28290486 http://dx.doi.org/10.1038/srep44229 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Ikuta, Yoshikazu
Aoyagi, Shigenobu
Tanaka, Yuji
Sato, Kota
Inada, Satoshi
Koseki, Yoshitaka
Onodera, Tsunenobu
Oikawa, Hidetoshi
Kasai, Hitoshi
Creation of nano eye-drops and effective drug delivery to the interior of the eye
title Creation of nano eye-drops and effective drug delivery to the interior of the eye
title_full Creation of nano eye-drops and effective drug delivery to the interior of the eye
title_fullStr Creation of nano eye-drops and effective drug delivery to the interior of the eye
title_full_unstemmed Creation of nano eye-drops and effective drug delivery to the interior of the eye
title_short Creation of nano eye-drops and effective drug delivery to the interior of the eye
title_sort creation of nano eye-drops and effective drug delivery to the interior of the eye
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349510/
https://www.ncbi.nlm.nih.gov/pubmed/28290486
http://dx.doi.org/10.1038/srep44229
work_keys_str_mv AT ikutayoshikazu creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT aoyagishigenobu creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT tanakayuji creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT satokota creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT inadasatoshi creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT kosekiyoshitaka creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT onoderatsunenobu creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT oikawahidetoshi creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye
AT kasaihitoshi creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye